Decreased expression of prenyl diphosphate synthase subunit 2 correlates with reduced survival of patients with gastric cancer
Tóm tắt
Identification of novel molecular biomarkers will improve the management of patients with gastric cancer (GC). Prenyl diphosphate synthase subunit 2 (PDSS2) is required for coenzyme Q10 biosynthesis and acts as a tumor suppressor; however, the role and regulatory mechanisms of PDSS2 in GC are not understood. The aim of this study was to determine expression status and regulatory mechanisms of PDSS2 in GC. Associations between expression and methylation of PDSS2 were evaluated using GC cell lines. The clinical significance of PDSS2 expression was evaluated using 238 pairs of surgically resected gastric tissues with subgroup analysis based on GC subtypes. The expression of PDSS2 mRNA was decreased in 73% of GC cell lines compared with the control non-cancerous cell. The PDSS2 promoter was hypermethylated in cells with decreased PDSS2 expression, and treating these cells with a methylation inhibitor reactivated PDSS2 expression. GC tissues expressed significantly lower mean levels of PDSS2 mRNA compared with adjacent normal tissues (P <0.001). The expression pattern of PDSS2 protein was consistent with that of its mRNA. The decrease of PDSS2 mRNA expression in GC tissues (less than half the level of expression detected in the corresponding normal adjacent tissues) correlated significantly with elevated levels of carbohydrate antigen 19-9 (P = 0.015), lymph node metastasis (P = 0.022), and shorter recurrence-free survival after curative resection (P = 0.022). Further, multivariate analysis identified PDSS2 mRNA expression as an independent prognostic factor (hazard ratio 1.95, 95% confidence interval 1.22–3.09, P = 0.005), and its expression pattern and prognostic significance were similar among three GC subtypes. PDSS2 encodes a putative tumor suppressor, and we show here that its expression was regulated by hypermethylation of its promoter in GC cells. Inhibition of PDSS2 mRNA expression may serve as a novel biomarker of all types of GC.
Tài liệu tham khảo
Wang Z, Wang J, Yang Y, Hao B, Wang R, Li Y, Wu Q: Loss of has-miR-337-3p expression is associated with lymph node metastasis of human gastric cancer. J Exp Clin Cancer Res 2013, 32: 76.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61: 69-90. 10.3322/caac.20107
Leung WK, Wu MS, Kakugawa Y, Kim JJ, Yeoh KG, Goh KL, Wu KC, Wu DC, Sollano J, Kachintorn U, Gotoda T, Lin JT, You WC, Ng EK, Sung JJ: Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol 2008, 9: 279-287. 10.1016/S1470-2045(08)70072-X
Kanda M, Nomoto S, Oya H, Shimizu D, Takami H, Hibino S, Hashimoto R, Kobayashi D, Tanaka C, Yamada S, Fujii T, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y: Dihydropyrimidinase-like 3 facilitates malignant behavior of gastric cancer. J Exp Clin Cancer Res 2014, 33: 66.
Wang YY, Li L, Zhao ZS, Wang YX, Ye ZY, Tao HQ: L1 and epithelial cell adhesion molecules associated with gastric cancer progression and prognosis in examination of specimens from 601 patients. J Exp Clin Cancer Res 2013, 32: 66.
Resende C, Thiel A, Machado JC, Ristimaki A: Gastric cancer: basic aspects. Helicobacter 2011,16(Suppl 1):38-44. 10.1111/j.1523-5378.2011.00879.x
Kanda M, Shimizu D, Nomoto S, Takami H, Hibino S, Oya H, Hashimoto R, Suenaga M, Inokawa Y, Kobayashi D, Tanaka C, Yamada S, Fujii T, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y: Prognostic impact of expression and methylation status of DENN/MADD domain-containing protein 2D in gastric cancer. Gastric Cancer 2014, Epub ahead of print, PubMed PMID: 24695972.
Lauren P: The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965, 64: 31-49.
Shah MA, Khanin R, Tang L, Janjigian YY, Klimstra DS, Gerdes H, Kelsen DP: Molecular classification of gastric cancer: a new paradigm. Clin Cancer Res 2011, 17: 2693-2701. 10.1158/1078-0432.CCR-10-2203
Saiki R, Nagata A, Kainou T, Matsuda H, Kawamukai M: Characterization of solanesyl and decaprenyl diphosphate synthases in mice and humans. Febs j 2005, 272: 5606-5622. 10.1111/j.1742-4658.2005.04956.x
Chen P, Yu J, Knecht J, Chen Q: Decrease of PDSS2 expression, a novel tumor suppressor, in non-small cell lung cancer. Cancer Epidemiol 2013, 37: 166-171. 10.1016/j.canep.2012.12.004
Fung JM, Smith R, Brown MA, Lau SH, Xie D, Lau GK, Guan XY: Identification and characterization of a novel melanoma tumor suppressor gene on human chromosome 6q21. Clin Cancer Res 2009, 15: 797-803. 10.1158/1078-0432.CCR-08-1472
Quinzii CM, DiMauro S, Hirano M: Human coenzyme Q10 deficiency. Neurochem Res 2007, 32: 723-727. 10.1007/s11064-006-9190-z
DiMauro S, Quinzii CM, Hirano M: Mutations in coenzyme Q10 biosynthetic genes. J Clin Invest 2007, 117: 587-589. 10.1172/JCI31423
Turunen M, Olsson J, Dallner G: Metabolism and function of coenzyme Q. Biochim Biophys Acta 2004, 1660: 171-199. 10.1016/j.bbamem.2003.11.012
Li BC, Chan WY, Li CY, Chow C, Ng EK, Chung SC: Allelic loss of chromosome 6q in gastric carcinoma. Diagn Mol Pathol 2003, 12: 193-200. 10.1097/00019606-200312000-00003
Carvalho B, Seruca R, Carneiro F, Buys CH, Kok K: Substantial reduction of the gastric carcinoma critical region at 6q16.3-q23.1. Genes Chromosomes Cancer 1999, 26: 29-34. 10.1002/(SICI)1098-2264(199909)26:1<29::AID-GCC4>3.0.CO;2-D
Chen P, Zhao SH, Chu YL, Xu K, Zhu L, Wu Y, Song J, Cao CX, Xue X, Niu YY: Anticancer activity of PDSS2, prenyl diphosphate synthase, subunit 2, in gastric cancer tissue and the SGC7901 cell line. Anticancer Drugs 2009, 20: 141-148. 10.1097/CAD.0b013e32832016a9
Sobin LH, Gospodarowicz MK: International Union Against Cancer, TNM Classification of Malignant Tumors. Wiley-Blackwell, New York; 2009.
Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007, 357: 1810-1820. 10.1056/NEJMoa072252
Kanda M, Nomoto S, Oya H, Takami H, Hibino S, Hishida M, Suenaga M, Yamada S, Inokawa Y, Nishikawa Y, Asai M, Fujii T, Sugimoto H, Kodera Y: Downregulation of DENND2D by promoter hypermethylation is associated with early recurrence of hepatocellular carcinoma. Int J Oncol 2014, 44: 44-52.
Kanda M, Nomoto S, Okamura Y, Nishikawa Y, Sugimoto H, Kanazumi N, Takeda S, Nakao A: Detection of metallothionein 1G as a methylated tumor suppressor gene in human hepatocellular carcinoma using a novel method of double combination array analysis. Int J Oncol 2009, 35: 477-483. 10.3892/ijo_00000448
Kanda M, Shimizu D, Nomoto S, Hibino S, Oya H, Takami H, Kobayashi D, Yamada S, Inokawa Y, Tanaka C, Fujii T, Sugimoto H, Koike M, Fujiwara M, Kodera Y: Clinical significance of expression and epigenetic profiling of TUSC1 in gastric cancer. J Surg Oncol 2014, 110: 136-144.
Takai D, Jones PA: The CpG island searcher: a new WWW resource. In Silico Biol 2003, 3: 235-240.
Kanda M, Nomoto S, Okamura Y, Hayashi M, Hishida M, Fujii T, Nishikawa Y, Sugimoto H, Takeda S, Nakao A: Promoter hypermethylation of fibulin 1 gene is associated with tumor progression in hepatocellular carcinoma. Mol Carcinog 2011, 50: 571-579. 10.1002/mc.20735
Queimado L, Seruca R, Costa-Pereira A, Castedo S: Identification of two distinct regions of deletion at 6q in gastric carcinoma. Genes Chromosomes Cancer 1995, 14: 28-34. 10.1002/gcc.2870140106
Nagai H, Pineau P, Tiollais P, Buendia MA, Dejean A: Comprehensive allelotyping of human hepatocellular carcinoma. Oncogene 1997, 14: 2927-2933. 10.1038/sj.onc.1201136
Chen P, Zhang Y, Polireddy K, Chen Q: The tumor-suppressing activity of the prenyl diphosphate synthase subunit 2 gene in lung cancer cells. Anticancer Drugs 2014, 25: 790-798. 10.1097/CAD.0000000000000105
An JH, Kim JW, Jang SM, Kim CH, Kang EJ, Choi KH: Gelsolin negatively regulates the activity of tumor suppressor p53 through their physical interaction in hepatocarcinoma HepG2 cells. Biochem Biophys Res Commun 2011, 412: 44-49. 10.1016/j.bbrc.2011.07.034
Jang BG, Kim WH: Molecular pathology of gastric carcinoma. Pathobiology 2011, 78: 302-310. 10.1159/000321703
Kim TY, Jong HS, Jung Y, Kim TY, Kang GH, Bang YJ: DNA hypermethylation in gastric cancer. Aliment Pharmacol Ther 2004,20(Suppl 1):131-142. 10.1111/j.1365-2036.2004.01984.x
To KF, Leung WK, Lee TL, Yu J, Tong JH, Chan MW, Ng EK, Chung SC, Sung JJ: Promoter hypermethylation of tumor-related genes in gastric intestinal metaplasia of patients with and without gastric cancer. Int J Cancer 2002, 102: 623-628. 10.1002/ijc.10783
Janjigian YY, Kelsen DP: Genomic dysregulation in gastric tumors. J Surg Oncol 2013, 107: 237-242. 10.1002/jso.23263
Bird A: Perceptions of epigenetics. Nature 2007, 447: 396-398. 10.1038/nature05913